Temsirolimus, sold under the brand name Torisel, is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the U.S. Food and Drug Administration (FDA) in May 2007, [3] and was also approved by the European Medicines Agency (EMA) in November 2007. [1]

TORISEL is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma. (1) The recommended dose of TORISEL is 25 mg administered as an intravenous infusion over a 30–60 minute period once a week. Treat until disease progression or unacceptable toxicity. (2.1) TORISEL injection, 25 mg/mL supplied with DILUENT for TORISEL. (3)

Visit www.torisel.com. Pfizer Oncology Together™ provides financial assistance resources to help patients access their prescribed Oncology medicines. for Healthcare professionals:

2023年8月23日 · Torisel is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Torisel is used to treat cancer of the kidneys, also called renal cell carcinoma. Torisel may also be used for purposes not listed in this medication guide.

TORISEL is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma. (1) The recommended dose of TORISEL is 25 mg administered as an intravenous infusion over a 30–60 minute period once a week. Treat until disease progression or unacceptable toxicity. (2.1) TORISEL injection, 25 mg/mL supplied with DILUENT for TORISEL. (3)

替西罗莫司（商品名为Torisel）是一种治疗 肾细胞癌(RCC) 的静脉注射药物，由惠氏制药公司研发，于 2007 年 5 月获得美国食品药品管理局(FDA) 批准，并于 2007 年 11 月获得欧洲药品管理局(EMA)批准。

Torisel is a medicine used to treat patients with the following types of cancer: advanced renal cell carcinoma (a kidney cancer). ‘Advanced’ means that the cancer has started to spread; mantle cell lymphoma (a cancer of B cells, a type of white blood cell).

TORISEL is administered as an intravenous infusion over a 30- to 60-minute period once weekly. The use of an infusion pump is the preferred method of administration to ensure accurate delivery of the product.

TORISEL is an inhibitor of mTOR approved in the European Union for the first-line treatment of patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors. TORISEL demonstrated a statistically significant increase in median overall survival (OS) compared with IFN-α.

2020年8月10日 · Torisel（temsirolimus）是雷帕霉素的衍生物，它是一种具有抗真菌，免疫抑制剂和抗肿瘤活性的药物。 Torisel似乎阻止mTOR的作用，mTOR是调节控制细胞分裂的蛋白质合成中起重要作用的酶。